Cargando…

Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?

The National Institute for Clinical Excellence (NICE) now recommends that continuous glucose monitoring (CGM) be offered to adults and children with diabetes who are at risk from hypoglycaemia. Hypoglycaemia is common in the neonatal period, and is a preventable cause of poor neurodevelopmental outc...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalogeropoulou, Maria-Sofia, Iglesias-Platas, Isabel, Beardsall, Kathryn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070986/
https://www.ncbi.nlm.nih.gov/pubmed/37025284
http://dx.doi.org/10.3389/fped.2023.1115228
_version_ 1785019101732667392
author Kalogeropoulou, Maria-Sofia
Iglesias-Platas, Isabel
Beardsall, Kathryn
author_facet Kalogeropoulou, Maria-Sofia
Iglesias-Platas, Isabel
Beardsall, Kathryn
author_sort Kalogeropoulou, Maria-Sofia
collection PubMed
description The National Institute for Clinical Excellence (NICE) now recommends that continuous glucose monitoring (CGM) be offered to adults and children with diabetes who are at risk from hypoglycaemia. Hypoglycaemia is common in the neonatal period, and is a preventable cause of poor neurodevelopmental outcome, but is CGM helpful in the management of neonates at risk of hypoglycaemia? Neonatal studies have shown that CGM can detect clinically silent hypoglycaemia, which has been associated with reduced executive and visual function in early childhood. Intervention trials have further shown CGM can support the targeting of glucose levels in high-risk extremely preterm neonates. In spite of significant advances in technology, including smaller sensors, better accuracy and factory calibration, further progress and adoption into clinical practice has been limited as current devices are not designed nor have regulatory approval for the specific needs of the newborn. The use of CGM has the potential to support clinical management, and prevention of hypoglycaemia but must be set within its current limitations. The data CGM provides however also provides an important opportunity to improve our understanding of potential risks of hypoglycaemia and the impact of clinical interventions to prevent it.
format Online
Article
Text
id pubmed-10070986
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-100709862023-04-05 Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia? Kalogeropoulou, Maria-Sofia Iglesias-Platas, Isabel Beardsall, Kathryn Front Pediatr Pediatrics The National Institute for Clinical Excellence (NICE) now recommends that continuous glucose monitoring (CGM) be offered to adults and children with diabetes who are at risk from hypoglycaemia. Hypoglycaemia is common in the neonatal period, and is a preventable cause of poor neurodevelopmental outcome, but is CGM helpful in the management of neonates at risk of hypoglycaemia? Neonatal studies have shown that CGM can detect clinically silent hypoglycaemia, which has been associated with reduced executive and visual function in early childhood. Intervention trials have further shown CGM can support the targeting of glucose levels in high-risk extremely preterm neonates. In spite of significant advances in technology, including smaller sensors, better accuracy and factory calibration, further progress and adoption into clinical practice has been limited as current devices are not designed nor have regulatory approval for the specific needs of the newborn. The use of CGM has the potential to support clinical management, and prevention of hypoglycaemia but must be set within its current limitations. The data CGM provides however also provides an important opportunity to improve our understanding of potential risks of hypoglycaemia and the impact of clinical interventions to prevent it. Frontiers Media S.A. 2023-03-21 /pmc/articles/PMC10070986/ /pubmed/37025284 http://dx.doi.org/10.3389/fped.2023.1115228 Text en © 2023 Kalogeropoulou, Iglesias-Platas and Beardsall. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Kalogeropoulou, Maria-Sofia
Iglesias-Platas, Isabel
Beardsall, Kathryn
Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
title Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
title_full Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
title_fullStr Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
title_full_unstemmed Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
title_short Should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
title_sort should continuous glucose monitoring be used to manage neonates at risk of hypoglycaemia?
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070986/
https://www.ncbi.nlm.nih.gov/pubmed/37025284
http://dx.doi.org/10.3389/fped.2023.1115228
work_keys_str_mv AT kalogeropouloumariasofia shouldcontinuousglucosemonitoringbeusedtomanageneonatesatriskofhypoglycaemia
AT iglesiasplatasisabel shouldcontinuousglucosemonitoringbeusedtomanageneonatesatriskofhypoglycaemia
AT beardsallkathryn shouldcontinuousglucosemonitoringbeusedtomanageneonatesatriskofhypoglycaemia